Stereotactic radiotherapy in the treatment of lung metastases from bone and soft-tissue sarcomas

Rezarta Frakulli, Fabrizio Salvi, Damiano Balestrini, Alessandro Parisi, Marcella Palombarini, Silvia Cammelli, Michele Rocca, Mariacristina Salone, Alessandra Longhi, Stefano Ferrari, Alessio G. Morganti, Giovanni Frezza

Research output: Contribution to journalArticlepeer-review


Background: The purpose of this study was to evaluate local control and toxicity in a group of patients treated with stereotactic body radiotherapy (SBRT) for lung metastases (LM) from bone and soft tissue sarcomas. Patients and Methods: From October 2010 to July 2014, patients with LM from sarcomas not suitable for surgery were treated with daily cone-beam computed tomographyguided SBRT. The dose administered ranged from 30 to 60 Gy in 3-8 fractions. Acute and late toxicity were scored according to Common Terminology Criteria for Adverse Events version 4.0. Results: A total of 24 patients with 68 LM from sarcomas were treated with SBRT. The median follow-up after SBRT was 17 months (range=11-51 months). Two-year actuarial lesion local control and overall survival were 85.9% and 66.4%, respectively. No G3 or greater acute and late toxicities were observed. Conclusion: SBRT is a safe and effective treatment for LM from sarcoma and might be used as an alternative option in patients unfit for surgery.

Original languageEnglish
Pages (from-to)5581-5586
Number of pages6
JournalAnticancer Research
Issue number10
Publication statusPublished - Oct 1 2015


  • Lung metastases
  • Sarcoma
  • SBRT

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)


Dive into the research topics of 'Stereotactic radiotherapy in the treatment of lung metastases from bone and soft-tissue sarcomas'. Together they form a unique fingerprint.

Cite this